

for diagnosis, prophylaxis and management of *Pneumocystis jirovecii* pneumonia in patients with haematological and solid malignancies, 2014. *Interní Med J.* 2014;44(12b):1350-1363. doi: 10.1111/imj.12599.

243. Fei N, Shah N, Cumpston A, et al. Low-Dose Acyclovir Prophylaxis for Varicella zoster. Reactivation in Autologous Hematopoietic Cell Transplantation Recipients. *Clin Hematol Int.* 2019;1(2):101-104. doi: 10.2991/chi.d.190329.001.

244. Wada-Shimosato Y, Tanoshima R, Hiratoko K, et al. Effectiveness of acyclovir prophylaxis against varicella zoster virus disease after allogeneic hematopoietic cell transplantation: A systematic review and meta-analysis. *Transpl Infect Dis.* 2019;21(3):e13061. doi: 10.1111/tid.13061.

245. Drgona L, Gudiol C, Lanini S, et al. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid or myeloid cells surface antigens [II]: CD22, CD30, CD33, CD38, CD40, SLAMF-7 and CCR4). *Clin Microbiol Infect.* 2018;24(Suppl 2):S83-S94. doi: 10.1016/j.cmi.2018.03.022.

246. Khan S, Vaisman A, Hota SS, Bennett S, Trudel S, Reece D, Tiedemann RE. *Listeria* Susceptibility in Patients With Multiple Myeloma Receiving Daratumumab-Based Therapy. *JAMA Oncol.* 2020;6(2):293-294. doi: 10.1001/jamaoncol.2019.5098.

247. Nakagawa R, Onishi Y, Kawajiri A, et al. Preemptive therapy for cytomegalovirus reactivation after daratumumab-containing treatment in patients with relapsed and refractory multiple myeloma. *Ann Hematol.* 2019;98(8):1999-2001. doi: 10.1007/s00277-019-03645-7.

248. Terpos E, Engelhardt M, Cook G, et al. Management

of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN). *Leukemia.* 2020;34(8):2000-2011. doi: 10.1038/s41375-020-0876-z.

249. Kuzume A, Tabata R, Terao T, et al. Safety and efficacy of daratumumab in patients with multiple myeloma and severe renal failure. *Br J Haematol.* 2021;193(4):e33-e36. doi: 10.1111/bjh.17412.

250. Rocchi S, Tacchetti P, Pantani L, et al. Safety and efficacy of daratumumab in dialysis-dependent renal failure secondary to multiple myeloma. *Haematologica.* 2018;103(6):e277-e278. doi:10.3324/haematol.2018.191122.

251. Jeyaraman P, Bhasin A, Dayal N, et al. Daratumumab in dialysis-dependent multiple myeloma. *Blood Res.* 2020;55(1):65-67. doi: 10.5045/br.2020.55.1.65.

252. Saengsirinavin AO, Wutthayakorn W, Chansangpet S, et al. Acute bilateral angle closure induced by monoclonal antibody (Daratumumab) infusion. *Am J Ophthalmol Case Rep.* 2021;22:101079. doi:10.1016/j.ajoc.2021.101079.

253. Nadeau Nguyen M, Chambers W, Dores GM, et al. Association of Daratumumab Use With Ocular Events in a Case Series of US Adults. *JAMA Oncol.* e221634. doi: 10.1001/jamaoncol.2022.1634.

254. Cho J, Siegel N, Subramanian ML, et al. Rapidly progressive neovascular glaucoma from cytomegalovirus retinitis in non-human immunodeficiency virus patient. *Retin Cases Brief Rep.* 2021;15(1):62-64. doi: 10.1097/ICB.0000000000000734.

255. Minařík J, Novák J, Flodr P, et al. CD38-negative relapse in multiple myeloma after daratumumab-based chemotherapy. *European journal of haematology.* 2017;99(2):186-189.

256. Nijhof IS, Casneuf T, Van Velzen J, et al. CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma. *Blood, Am J Hematol.* 2016;128:959-970.

257. Saltarella I, Desantis V, Melaccio A, et al. Mechanisms of resistance to anti-CD38 daratumumab in multiple myeloma. *Cells.* 2020;9(1):167-170.

258. Wang Y, Zhang Y, Hughes T, et al. Fratricide of NK cells in daratumumab therapy for multiple myeloma overcome by ex vivo-expanded autologous NK cells. *Clin Cancer Res.* 2018;24:4006-4017.

259. Chao MP, Alizadeh AA, Tang C, et al. Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma. *Cell.* 2010;142:699-713.

260. Rendtew Danielsen JM, Knudsen LM, Dahl IM, et al. Dysregulation of CD47 and the ligands thrombospondin 1 and 2 in multiple myeloma. *Br J Haematol.* 2007;138:756-760.

261. Syed YY. Daratumumab: A Review in Combination Therapy for Transplant-Ineligible Newly Diagnosed Multiple Myeloma. *Drugs.* 2019;79(4):447-454. doi: 10.1007/s40265-019-01080-6.

262. Bapatla A, Kaul A, Dhalla PS, et al. Role of Daratumumab in Combination With Standard Therapies in Patients With Relapsed and Refractory Multiple Myeloma. *Cureus.* 2021;13(6):e15440. doi: 10.7759/cureus.15440.

263. Lamb YN. Daratumumab: A Review in Combination Therapy for Transplant-Eligible Newly Diagnosed Multiple Myeloma. *Drugs.* 2020;80(14):1455-1464. doi: 10.1007/s40265-020-01385-x.